drugset / Trial / NCT04163302
Safety and Efficiency Study of CD19-PD1-CART Cell in Relapsed/Refractory B Cell Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
This is a single center, non-randomized, open-label, phase 2 study to evaluate the efficacy and safety of CD19-PD1-CART cells therapy for patients with relapsed/refractory B Cell Lymphoma.
Timeline
- Start
- 2019-07-07
- Primary completion
- 2021-07-01
- Completion
- 2022-07-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CD19-PD1-CART Cell | Cell therapy | — | Other |